```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSPTASXS1656

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * *
* *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 08   CHEMLIST enhanced with New Zealand Inventory of
Chemicals
 NEWS  3  JAN 16   CA/CAplus Company Name Thesaurus enhanced and
reloaded
 NEWS  4  JAN 16   IPC version 2007.01 thesaurus available on STN
 NEWS  5  JAN 16   WPIDS/WPINDEX/WPIX enhanced with IPC 8
reclassification data
 NEWS  6  JAN 22   CA/CAplus updated with revised CAS roles
 NEWS  7  JAN 22   CA/CAplus enhanced with patent applications from
India
 NEWS  8  JAN 29   PHAR reloaded with new search and display fields
 NEWS  9  JAN 29   CAS Registry Number crossover limit increased to
300,000 in
                   multiple databases
 NEWS 10  FEB 15   PATDPASPC enhanced with Drug Approval numbers
 NEWS 11  FEB 15   RUSSIAPAT enhanced with pre-1994 records
 NEWS 12  FEB 23   KOREAPAT enhanced with IPC 8 features and
functionality
 NEWS 13  FEB 26   MEDLINE reloaded with enhancements
 NEWS 14  FEB 26   EMBASE enhanced with Clinical Trial Number field
 NEWS 15  FEB 26   TOXCENTER enhanced with reloaded MEDLINE
 NEWS 16  FEB 26   IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 17  FEB 26   CAS Registry Number crossover limit increased from
10,000
                   to 300,000 in multiple databases
 NEWS 18  MAR 15   WPIDS/WPIX enhanced with new FRAGHITSTR display
format
 NEWS 19  MAR 16   CASREACT coverage extended
 NEWS 20  MAR 20   MARPAT now updated daily
 NEWS 21  MAR 22   LWPI reloaded
 NEWS 22  MAR 30   RDISCLOSURE reloaded with enhancements
 NEWS 23  APR 02   JICST-EPLUS removed from database clusters and STN
 NEWS 24  APR 30   GENBANK reloaded and enhanced with Genome Project
ID field
```

```
 NEWS 25  APR 30  CHEMCATS enhanced with 1.2 million new records
 NEWS 26  APR 30  CA/CAplus enhanced with 1870-1889 U.S. patent
records
 NEWS 27  APR 30  INPADOC replaced by INPADOCDB on STN
 NEWS 28  MAY 01  New CAS web site launched
 NEWS 29  MAY 08  CA/CAplus Indian patent publication number format
defined
 NEWS 30  MAY 14  RDISCLOSURE on STN Easy enhanced with new search
and display
                  fields
 NEWS 31  MAY 21  BIOSIS reloaded and enhanced with archival data
 NEWS 32  MAY 21  TOXCENTER enhanced with BIOSIS reload
 NEWS 33  MAY 21  CA/CAplus enhanced with additional kind codes for
German
                  patents
 NEWS 34  MAY 22  CA/CAplus enhanced with IPC reclassification in
Japanese
                  patents

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation
of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *
* *

FILE 'HOME' ENTERED AT 18:30:36 ON 08 JUN 2007

=> File Medline EMBASE Biosis Caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 18:30:52 ON 08 JUN 2007

FILE 'EMBASE' ENTERED AT 18:30:52 ON 08 JUN 2007
```

```
FILE 'BIOSIS' ENTERED AT 18:30:52 ON 08 JUN 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 18:30:52 ON 08 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (casein kinase I) (w) (gamma or g)
L1          45 (CASEIN KINASE I) (W) (GAMMA OR G)

=> s (casein kinase 1) (w) (gamma or g)
L2          20 (CASEIN KINASE 1) (W) (GAMMA OR G)

=> s l1 or l2
L3          63 L1 OR L2

=> s l3 (8A)  (p21 or WAF1 or CIP1)
L4           1 L3 (8A) (P21 OR WAF1 OR CIP1)

=> d l4 bib ab

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2004:143261  CAPLUS
DN   140:176313
TI   casein kinase I gamma-1 isoforms
     (CSNK1G1s) as modifiers of the p21 pathway and uses thereof in
     diagnosis, therapy and drug screening
IN   Francis-Lang, Helen; Friedman, Lori; Kidd, Thomas; Roche,
Siobhan; Zhang,
     Haiguang
PA   Exelixis, Inc., USA
SO   PCT Int. Appl., 69 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 8
     PATENT NO.          KIND   DATE        APPLICATION NO.
DATE
     --------------      ----   --------    -------------------
--------
PI   WO 2004015071        A2    20040219    WO 2003-US24551
20030806
     WO 2004015071        A3    20040812
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR,
```

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2494236 A1 20040219 CA 2003-2494236 20030806

AU 2003263995 A1 20040225 AU 2003-263995 20030806

EP 1534852 A2 20050601 EP 2003-784937 20030806

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005534334 T 20051117 JP 2004-527773 20030806

US 2005251870 A1 20051110 US 2005-523588 20050204

PRAI US 2002-401739P P 20020807

WO 2003-US24551 W 20030806

AB The invention has designed a dominant loss of function screen to identify genes that interact with the cyclin dependent kinase inhibitor p21 in Drosophila. Casein kinase I gamma-1 isoform 3 (CSNK1G1) gene was identified as a modifier of the p21 pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, casein kinase I gamma-1 isoform (CSNK1G1) genes are attractive drag targets for the treatment of pathologies associated with a defective p21 signaling pathway, such as cancer. The invention also provides methods for utilizing these p21 modifier genes and polypeptides to identify candidate therapeutic agents that can be used in the treatment of disorders associated with defective p21 function.

=> s l3 (P) (p21 or WAF1 or CIP1)

```
L5             4 L3 (P) (P21 OR WAF1 OR CIP1)

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l5
DUPLICATE PREFERENCE IS 'EMBASE, BIOSIS, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L5
L6             2 DUPLICATE REMOVE L5 (2 DUPLICATES REMOVED)

=> d l6 1-2 bib ab

L6   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2004:143261  CAPLUS
DN   140:176313
TI   casein kinase I gamma-1 isoforms
     (CSNK1G1s) as modifiers of the p21 pathway and uses thereof in
     diagnosis, therapy and drug screening
IN   Francis-Lang, Helen; Friedman, Lori; Kidd, Thomas; Roche,
Siobhan; Zhang,
     Haiguang
PA   Exelixis, Inc., USA
SO   PCT Int. Appl., 69 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 8
     PATENT NO.          KIND   DATE        APPLICATION NO.
DATE
     --------------      ----   --------    --------------------
--------
PI   WO 2004015071        A2    20040219    WO 2003-US24551
20030806
     WO 2004015071        A3    20040812
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,
SK, TR,
```

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2494236 A1 20040219 CA 2003-2494236 20030806
AU 2003263995 A1 20040225 AU 2003-263995 20030806
EP 1534852 A2 20050601 EP 2003-784937 20030806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005534334 T 20051117 JP 2004-527773 20030806
US 2005251870 A1 20051110 US 2005-523588 20050204
PRAI US 2002-401739P P 20020807
WO 2003-US24551 W 20030806
AB The invention has designed a dominant loss of function screen to identify genes that interact with the cyclin dependent kinase inhibitor p21 in Drosophila. Casein kinase I gamma-1 isoform 3 (CSNK1G1) gene was identified as a modifier of the p21 pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, casein kinase I gamma-1 isoform (CSNK1G1) genes are attractive drag targets for the treatment of pathologies associated with a defective p21 signaling pathway, such as cancer. The invention also provides methods for utilizing these p21 modifier genes and polypeptides to identify candidate therapeutic agents that can be used in the treatment of disorders associated with defective p21 function.

L6 ANSWER 2 OF 2 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 1
AN 1999268046 EMBASE
TI Angiotensin II stimulates serine phosphorylation of the adaptor protein Nck: Physical association with the serine/threonine kinases Pak1 and casein kinase I.
AU Voisin L.; Larose L.; Meloche S.
CS S. Meloche, Centre de Recherche, Centre hospitalier Univ. de Montreal, Campus Hotel-Dieu, 3850 St. Urbain, Montreal, Que. H2W 1T8, Canada.
meloches@ere.umontreal.ca

SO Biochemical Journal, (1 Jul 1999) Vol. 341, No. 1, pp. 217-223. .
Refs: 44
ISSN: 0264-6021 CODEN: BIJOAK
CY United Kingdom
DT Journal; Article
FS 029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 12 Aug 1999
Last Updated on STN: 12 Aug 1999
AB Nck is a small adaptor protein consisting exclusively of three SH3 domains and one SH2 domain. Nck is thought to have an important role in cell signalling by coupling receptor tyrosine kinases, via its SH2 domain, to downstream SH3-binding effectors. We report here that angiotensin II, working through the AT1 receptor subtype, stimulates the phosphorylation of Nck in rat aortic smooth muscle cells. Phosphopeptide mapping analysis revealed that Nck is phosphorylated on four peptides containing exclusively phosphoserine in quiescent cells. Treatment with angiotensin II resulted in increased phosphorylation of these four peptides, without the appearance of new phosphopeptides. We show that Nck, via its SH3 domains, specifically binds three major phosphoproteins of 95, 82 and 66 kDa both in vitro and in intact cells. Notably, the phosphorylation of these Nck-binding proteins was found to increase in parallel with that of Nck on stimulation by angiotensin II. One candidate for the 66 kDa phosphoprotein is the serine/threonine kinase p21-activated kinase 1 (Pak1), which was found to form a stable complex with Nck in aortic smooth muscle cells. We have also identified the γ2 isoform of casein kinase I as another protein kinase that associates with Nck in these cells. These findings indicate that Nck is a target of G-protein-coupled receptors and suggest a role for Pak1 and casein kinase I-.gamma.2 in downstream signalling or regulation of the AT1 receptor.

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSPTASXS1656

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * *
* *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 08   CHEMLIST enhanced with New Zealand Inventory of
Chemicals
 NEWS  3  JAN 16   CA/CAplus Company Name Thesaurus enhanced and
reloaded
 NEWS  4  JAN 16   IPC version 2007.01 thesaurus available on STN
 NEWS  5  JAN 16   WPIDS/WPINDEX/WPIX enhanced with IPC 8
reclassification data
 NEWS  6  JAN 22   CA/CAplus updated with revised CAS roles
 NEWS  7  JAN 22   CA/CAplus enhanced with patent applications from
India
 NEWS  8  JAN 29   PHAR reloaded with new search and display fields
 NEWS  9  JAN 29   CAS Registry Number crossover limit increased to
300,000 in
                   multiple databases
 NEWS 10  FEB 15   PATDPASPC enhanced with Drug Approval numbers
 NEWS 11  FEB 15   RUSSIAPAT enhanced with pre-1994 records
 NEWS 12  FEB 23   KOREAPAT enhanced with IPC 8 features and
functionality
 NEWS 13  FEB 26   MEDLINE reloaded with enhancements
 NEWS 14  FEB 26   EMBASE enhanced with Clinical Trial Number field
 NEWS 15  FEB 26   TOXCENTER enhanced with reloaded MEDLINE
 NEWS 16  FEB 26   IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 17  FEB 26   CAS Registry Number crossover limit increased from
10,000
                   to 300,000 in multiple databases
 NEWS 18  MAR 15   WPIDS/WPIX enhanced with new FRAGHITSTR display
format
 NEWS 19  MAR 16   CASREACT coverage extended
 NEWS 20  MAR 20   MARPAT now updated daily
 NEWS 21  MAR 22   LWPI reloaded
 NEWS 22  MAR 30   RDISCLOSURE reloaded with enhancements
 NEWS 23  APR 02   JICST-EPLUS removed from database clusters and STN
 NEWS 24  APR 30   GENBANK reloaded and enhanced with Genome Project
ID field
```